Spain-based Quibim has launched QP-Breast, a CE and UKCA-marked AI tool for detecting breast cancer using MRI in Europe and the UK. The solution automatically identifies suspected lesions on breast MRI scans, generating structured reports with lesion size, volume, location, and likelihood of malignancy.
Breast MRI plays a growing role in screening high-risk patients and those with dense breast tissue. But rising scan volumes and workforce shortages are straining radiology teams, and interpretation variability can delay diagnosis. Up to 4 out of 5 biopsied breast lesions turn out not to be cancer, leading to unnecessary procedures, costs, and patient stress.
QP-Breast is designed to help radiologists read scans faster and more consistently, automatically highlighting suspicious areas and integrating directly into existing hospital systems. The tool is suitable for both screening and diagnostic MRI.
“Radiology teams are facing growing demand, but resources aren’t keeping pace,” said CEO Dr. Ángel Alberich-Bayarri. “By automating time-consuming parts of MRI analysis and delivering clear, structured outputs, we’re enabling radiologists to focus on what matters most.”
QP-Breast is CE marked as a Class IIb medical device under EU MDR and UKCA marked as Class IIa, available across Europe and the UK. Quibim’s products are used across more than 470 sites globally, including its QP Prostate tool which holds FDA 510(k) clearance.
